Check Your Eligibility

Answer a few questions to see if you may qualify for this trial.

Step 1 of 8

Do you have histologically confirmed melanoma (skin cancer) that is either unresectable or metastatic, AND have you previously been treated with a PD-1 antibody (such as nivolumab or pembrolizumab) that did not work or stopped working?

This trial is designed for melanoma patients whose cancer has progressed despite prior PD-1 antibody treatment. If you have uveal melanoma (eye melanoma), prior PD-1 treatment is not required. If you don't have melanoma or haven't had PD-1 treatment, you may still qualify for other cohorts in this study.

Show original medical criteria

Cohort A requires histologically confirmed, unresectable or metastatic melanoma refractory or relapsed after PD-1 antibody treatment

This is informational only — not medical advice. Always discuss eligibility with your oncologist.

Eligibility Check — A Study of APG-115 in as a Monotherapy or Combination With Pembrolizumab in Patients With Metastatic Melanomas or Advanced Solid Tumors — FindMyCure.ai